comparemela.com

Latest Breaking News On - Pherecydes pharma sadir - Page 1 : comparemela.com

Pherecydes Pharma Announces a First Registration of Its Phagogram as an in Vitro Diagnostic Test in Accordance With EC Directives

12.09.2022 - Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the registration of its phagogram as .

France
French
Pherecydes-pharma
Didier-hoch
French-national-agency
Pherecydes-pharma-sadir

The PhagECOLI Project Undertaken by Pherecydes Pharma and the CEA Receives a €2 Million Grant From Bpifrance

03.01.2022 - Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, and the CEA, today announced the selection of the PhagECOLI . Seite 1

Pherecydes-pharma
World-health-organization
European-centre-for-disease-prevention
Regulatory-news
Emerging-infectious-diseases
New-radiological
Chemical-threat-call
European-centre
Disease-prevention
Pherecydes-pharma-sadir

Pherecydes Pharma Obtains ANSM Approval for its PhagoDAIR Program, the World's First Study in Precision Phage Therapy Seite 1

22.12.2021 - Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has obtained ANSM (French . Seite 1

France
Spain
Pherecydes-pharma
Patient-protection-committee
Implant-retention
Protection-committee
Pherecydes-pharma-sadir

vimarsana © 2020. All Rights Reserved.